Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Trial to Evaluate the Efficacy of Anti-CD20 Antibody in Patients With Lymphocyte Predominant Hodgkin's Disease

NCT00003820 is registered in ClinicalTrials.gov with Ranjana Advani as lead sponsor.

NCT NCT00003820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Trial to Evaluate the Efficacy of Anti-CD20 Antibody in Patients With Lymphocyte Predominant Hodgkin's Disease
Lead sponsor
Ranjana Advani
Phase
Phase 2
Overall status
Completed
Start date
January 31, 1999
Completion date
August 31, 2008
Enrollment
39 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma (category), lymphoma, nodular lymphocyte predominant hodgkin lymphoma